Cargando…
Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330188/ https://www.ncbi.nlm.nih.gov/pubmed/28260862 http://dx.doi.org/10.2147/DDDT.S130945 |
_version_ | 1782511211916558336 |
---|---|
author | Mir, Fazia Kahveci, Alp S Ibdah, Jamal A Tahan, Veysel |
author_facet | Mir, Fazia Kahveci, Alp S Ibdah, Jamal A Tahan, Veysel |
author_sort | Mir, Fazia |
collection | PubMed |
description | Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinical trials of the once-daily combination tablet of sofosbuvir, a nonstructural (NS) 5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor, demonstrate sustained virologic response rates of about 95%, regardless of prior treatment experience or presence of cirrhosis across all HCV genotypes. Patients reported improvements in general health, fatigue, and emotional and mental well-being after completing combination therapy. The combination treatment is effective, but does need to be administered with caution in patients receiving certain medications or with certain diseases. Herein, we review the safety and efficacy of sofosbuvir/velpatasvir combination regimen for all HCV genotypes. |
format | Online Article Text |
id | pubmed-5330188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53301882017-03-03 Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure Mir, Fazia Kahveci, Alp S Ibdah, Jamal A Tahan, Veysel Drug Des Devel Ther Review Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinical trials of the once-daily combination tablet of sofosbuvir, a nonstructural (NS) 5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor, demonstrate sustained virologic response rates of about 95%, regardless of prior treatment experience or presence of cirrhosis across all HCV genotypes. Patients reported improvements in general health, fatigue, and emotional and mental well-being after completing combination therapy. The combination treatment is effective, but does need to be administered with caution in patients receiving certain medications or with certain diseases. Herein, we review the safety and efficacy of sofosbuvir/velpatasvir combination regimen for all HCV genotypes. Dove Medical Press 2017-02-23 /pmc/articles/PMC5330188/ /pubmed/28260862 http://dx.doi.org/10.2147/DDDT.S130945 Text en © 2017 Mir et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Mir, Fazia Kahveci, Alp S Ibdah, Jamal A Tahan, Veysel Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure |
title | Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure |
title_full | Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure |
title_fullStr | Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure |
title_full_unstemmed | Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure |
title_short | Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure |
title_sort | sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis c virus cure |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5330188/ https://www.ncbi.nlm.nih.gov/pubmed/28260862 http://dx.doi.org/10.2147/DDDT.S130945 |
work_keys_str_mv | AT mirfazia sofosbuvirvelpatasvirregimenpromisesaneffectivepangenotypichepatitiscviruscure AT kahvecialps sofosbuvirvelpatasvirregimenpromisesaneffectivepangenotypichepatitiscviruscure AT ibdahjamala sofosbuvirvelpatasvirregimenpromisesaneffectivepangenotypichepatitiscviruscure AT tahanveysel sofosbuvirvelpatasvirregimenpromisesaneffectivepangenotypichepatitiscviruscure |